TMB is expected to be a useful biomarker for immunotherapy of various lymphomas, and our findings suggest that patients with high grade B-cell lymphoma (PMLBL, CNS DLBCL etc.)and some T/NK-cell lymphoma (ALCL, ALK-negative etc.)are most likely to respond to immunotherapy. This evidence concerns the gene ALK and lymphoma.